155 related articles for article (PubMed ID: 36789960)
1. Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection.
Li C; Hall TG; Hall JJ; He WQ
Epidemiol Infect; 2023 Feb; 151():e37. PubMed ID: 36789960
[TBL] [Abstract][Full Text] [Related]
2. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
3. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
Kudo R; Sekine M; Yamaguchi M; Hara M; Hanley SJB; Kurosawa M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
Cancer Sci; 2022 Sep; 113(9):3211-3220. PubMed ID: 35730321
[TBL] [Abstract][Full Text] [Related]
6. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
8. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
Closson K; Karim ME; Sadarangani M; Naus M; Ogilvie GS; Donken R
Vaccine; 2020 Dec; 38(52):8396-8404. PubMed ID: 33239227
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
10. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
12. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
13. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
14. High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018.
Stefanos R; Lewis RM; Querec TD; Gargano JW; Unger ER; Markowitz LE
Hum Vaccin Immunother; 2024 Dec; 20(1):2308378. PubMed ID: 38372273
[TBL] [Abstract][Full Text] [Related]
15. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.
Kurosawa M; Sekine M; Yamaguchi M; Kudo R; Hanley SJB; Hara M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
Cancer Sci; 2022 Apr; 113(4):1435-1440. PubMed ID: 35100477
[TBL] [Abstract][Full Text] [Related]
17. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL
Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
19. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
